Objective To evaluate the safety and efficacy of cangrelor compared with GPIIb/IIIa inhibitors in large vessel occlusion stroke (LVOS). Methods This retrospective analysis from the Endovascular ...

Abstract: A new approach for occlusion-robust 3D human mesh reconstruction from a single image is introduced in this paper. Since occlusion has emerged as a major problem to be resolved in this field, ...

The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...

© 2025 American Heart Association, Inc. Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland (D.J.S., E.A.). Graduate School ...

The drivers of this effect remain unclear. One plausible mechanism is that high-dose upright activity worsens cerebral perfusion in patients with cerebral large vessel occlusion (LVO). For this ...

The sBLA seeks approval for Eylea HD to treat patients with macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every 4-week (monthly) dosing across ...

The FDA's priority review of EYLEA HD targets macular edema post retinal vein occlusion and monthly dosing expansion. EYLEA HD's extended dosing intervals maintain efficacy, reducing treatment burden, ...